Resumo:
Um estudo de Fase 3, randomizado, duplo-cego, controlado por placebo e multicêntrico, comparando niraparibe mais pembrolizumabe versus placebo mais pembrolizumabe como terapia de manutenção em participantes cuja doença permaneceu estável ou respondeu à quimioterapia de primeira linha à base de platina com pembrolizumabe para estágio IIIb ou IV câncer de pulmão de células não pequenas
Resumo:
São Paulo/SP
Instituição: IDOR São Paulo
Informações: 11 94257-9076 (WhatsApp) / 11 2109-8804
E-mail: nucleodecaptacao@idor.org
Cookie | Duração | Descrição |
---|---|---|
cookielawinfo-checkbox-analytics | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics". |
cookielawinfo-checkbox-functional | 11 months | The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". |
cookielawinfo-checkbox-necessary | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary". |
cookielawinfo-checkbox-others | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. |
cookielawinfo-checkbox-performance | 11 months | This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance". |
viewed_cookie_policy | 11 months | The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data. |